Meta-analysis of PRL-3 overexpression and prognosis in gastric cancer patients.

<p>All pooled <i>HR</i><b><i>s</i></b> were derived from random-effect model.</p><p><i>P</i>_h<i>P</i>-value for heterogeneity based on <b><i>Q</i></b> test.</p><p><i>P P</i>-value for statistical significance based on <b><i>Z</i></b> test.</p

Flow diagram of the study selection process and specific reasons for exclusion in the meta-analysis.

<p>Flow diagram of the study selection process and specific reasons for exclusion in the meta-analysis.</p

Poor Prognosis of Phosphatase of Regenerating Liver 3 Expression in Gastric Cancer: A Meta-Analysis

<div><p>Background</p><p>Overexpression of phosphatase of regenerating liver 3 (PRL-3) has been implicated in gastric cancer (GC) metastasis. Epidemiological studies have evaluated the relationship between PRL-3 expression and prognosis in GC. However, results still remains controversial. In this study, a meta-analysis was performed to evaluate the association of PRL-3 expression with overall survival (OS) and clinicopathological characteristics.</p><p>Methods</p><p>Literature databases were searched to identify eligible studies dated until April 2013. Summary hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to estimate the association.</p><p>Results</p><p>A total of 1380 GC patients from six studies were included in the meta-analysis. Overall, the combined HR estimate for OS in a random-effect model was 1.89 (95% CI = 1.38–2.60; <i>P</i><0.001). Results showed that PRL-3 overexpression was significantly associated with OS, indicating that it may be a biomarker for poor prognosis of GC. Both subgroup and sensitivity analyses further identified the prognostic role of PRL-3 expression in GC patients. Moreover, PRL-3 overexpression was significantly associated with tumor stage (OR = 2.25; 95% CI = 1.63–3.12; <i>P</i><0.001), depth of invasion (OR = 2.03; 95% CI = 1.38–2.98; <i>P</i><0.001), vascular invasion (OR = 2.52; 95% CI = 1.79–3.56; <i>P</i><0.001), lymphatic invasion (OR = 3.74; 95% CI = 2.49–5.63; <i>P</i><0.001), and lymph node metastasis (OR = 4.56; 95% CI = 2.37–8.76; <i>P</i><0.001). However, when age, sex, tumor size, and tumor differentiation were considered, no obvious association was observed.</p><p>Conclusions</p><p>This meta-analysis reveals significant association of PRL-3 overexpression with OS and some clinicopathological features in GC. PRL-3 may be a predicative factor of poor prognosis and aggressive tumor behavior in GC patients.</p></div

The forest plot for the overall association between PRL-3 overexpression and OS of GC patients.

<p>The contribution of each study to the meta-analysis (its weight) is represented by the <i>area</i> of a <i>box</i>, the <i>center</i> of which represents the size of the HR estimated from that study. The 95% CI for the HR (<i>extending lines</i>) from each study is also shown. The pooled HR is shown in the <i>middle</i> of a <i>diamond</i>, the <i>left</i> and <i>right</i> extremes of which represent the corresponding CI.</p

Flow diagram of study selection and specific reasons for exclusion in the meta-analysis.

<p>Flow diagram of study selection and specific reasons for exclusion in the meta-analysis.</p

The pooled AUC and 95% CI after omitting each trial in the meta-analysis (The results of sensitivity analysis).

<p>^a Results of first of two trials in this article</p><p>^b Results of second of two trials in this article</p><p>AUC: the area under the summary receiver operating characteristic curve; CI: confidence interval.</p><p>The pooled AUC and 95% CI after omitting each trial in the meta-analysis (The results of sensitivity analysis).</p

Main characteristic of 6 eligible studies enrolled in this meta-analysis.

<p><i>NR</i> data were not reported, <i>NS</i> not significant, <i>ISH</i> in situ hybridization, <i>IHC</i> immunohistochemistry,</p>a<p>directly extracted from original data,</p>b<p>extrapolated from survival curve.</p

The diagnostic parameters of presepsin for sepsis in the included trials, and overall outcome.

<p>^a Results of first of two trials in this article</p><p>^b Results of second of two trials in this article</p><p>TP: true positive; FP: false positive; FN: false negative; TN: true negative; Se: sensitivity; Sp: specificity; PLR: positive likelihood ratio; NLR: negative likelihood ratio; DOR: diagnostic odds ratio.</p><p>The diagnostic parameters of presepsin for sepsis in the included trials, and overall outcome.</p

Meta-analysis of the association between the 3801T>C polymorphism of CYP1A1 and risk for idiopathic male infertility under homozygous model.

<p>The contribution of each study to the meta-analysis (its weight) is represented by the area of a box, the center of which represents the size of the OR estimated from that study. The 95% CI for the OR (extending lines) from each study is also shown. The overall OR is shown in the middle of a diamond, the left and right extremes of which represent the corresponding CI.</p

Meta-analysis of PRL-3 overexpression and clinicopathological features in gastric cancer patients.

<p>All pooled <i>OR</i><b><i>s</i></b> were derived from random-effect model except for cells marked with (fixed^F).</p><p><i>P</i>_h<i>P</i>-value for heterogeneity based on <b><i>Q</i></b> test.</p><p><i>P P</i>-value for statistical significance based on <b><i>Z</i></b> test.</p